ABOUT PUTAI
Jiangsu Putai Pharmaceutical Technology Co., Ltd. was established in 2020 and is a modern high-tech enterprise specializing in the research and development, production, sales, and service of personal health care products. Relying on the strong R&D platform and unique technical advantages of its parent company Jiangsu Pulai Pharmaceutical Biotechnology Co., Ltd., we strive to build up its competitive advantages in terms of peptide products and technology, and are committed to becoming a benchmark enterprise in the industry that is close to people's families and improves the quality of healthy life. The company has been adhering to the business philosophy of integrity, standardization, and steady development. As of now, the company has launched over 30 products in four major series, ProteLight® Wenning series, ProteLight® Otty series, ProteLight® Flowtide antimicrobial series, ProteLight® Dr. Jun series, covering antibacterial skin care, oral care, private hygiene and other aspects of personal care and health. In the future, the company will continue to innovate and expand its product and service scope, develop more new products and series that are beneficial and effective for the public, meet people's increasingly diversified and personalized health needs, and serve public health.
![Putai Putai](/npublic/img/s.png)
Research and Products
Stay Healthy for a Better Life
ProteLight brand products have covered multiple sales channels including retail pharmacies, maternal and baby chain stores, convenience store systems, and online Tmall, JD, Pinduoduo, and AliHealth.In the future, Putai Pharma will develop more new products and series that benefit the people based on the ProteLight existing products, expand the market with high-quality innovative products.
![Putai Putai](/npublic/img/s.png)
High Quality
![Putai Putai](/npublic/img/s.png)
Innovation
![Putai Putai](/npublic/img/s.png)
Custom Service
NEWS
01
2020-09
Fully embrace new media and expand sales channels
With the rapid development of the information era, the marketing pattern of traditional offline channels has undergone profound changes under the impact of new media. Against this backdrop of development, Peptide Pharmaceuticals has further strengthened its confidence in development, focusing on private domain traffic to build a "micro-ecological chain" system. The New Media Sales Department was officially established on September 1, 2020.
14
2020-07
Warmly celebrate the establishment of Jiangsu Putai Pharmaceutical Technology Co., Ltd.
On July 14, 2020, in order to better accelerate the pace of enterprise new drug research and development and meet the increasing market demand for personal health products, Jiangsu ProteLight Pharmaceutical & Biotechnology Co., Ltd. (hereinafter referred to as Jiangsu Pulai) officially registered and established Jiangsu Pulai Pharmaceutical Technology Co., Ltd. (hereinafter referred to as Jiangsu Pulai). After the establishment of Jiangsu Peptide, it will definitely improve the company's innovative products, management level, and marketing strategy in response to the current market demand for personal care and health products from customers, further integrate resources, improve the response speed to customer needs, and make greater contributions to the development of the group business belonging to Jiangsu Peptide.
22
2017-09
The grand commencement ceremony for the construction of the new factory area was held
On September 22, 2017, the construction commencement ceremony for the company's new factory area located on Xingao Road in the High tech Zone of Jiangyin City was grandly held. Leaders from multiple departments of the Jiangyin Municipal Government and Chairman Chen Yuxin of the company attended the commencement ceremony. The new factory area will be constructed according to the standards of high starting point planning, high standard requirements, high-quality implementation, and efficient promotion. It is expected to enter production and use by 2019. The comprehensive operation of the new project will lay a solid foundation for the company's development. Under the strategic guidance of the chairman, the company will uphold the goal of high-quality development, continue to forge ahead, unite and collaborate, and strive to write new achievements that are realistic and innovative.